ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: FCRF Contract Hopefuls Make Oral Presentation; Jane Rowley To Deliver Karnofsky Lecture

April 10, 1987

Virus Cancer Program Includes “Some Of The Bes Basic Research Anywhere,” Moloney Says

January 9, 1976

AHRQ Draft Report Finds No Benefit For Biomarker Testing In Oncology

February 5, 2010

I-ELCAP Results Internally Inconsistent, Peter Bach Writes

June 24, 2011

NCI Cooperative Group Clinical Trials Approved

September 24, 2010

NIH Selects 16 Clinical Centers for Women’s Health Initiative

April 9, 1993